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Abstract 
 
Objective: We aimed to estimate the odds of engagement in HIV care and treatment among HIV-positive 
women reporting intimate partner violence (IPV). 
 
Design: We systematically reviewed the literature on the association between IPV and engagement in care. 
Data sources included searches of electronic databases (PubMed, Web of Science, CINAHL, and 
PsychoInfo), hand searches, and citation tracking.  
 
Methods: Two reviewers screened 757 full-text papers, extracted data, and independently appraised study 
quality. Included studies were peer-reviewed and assessed IPV alongside engagement in care outcomes: 
antiretroviral treatment (ART) use; self-reported ART adherence; viral suppression; retention in HIV care. 
Odds ratios (OR) were pooled using random effects meta-analysis. 
 
Results: Thirteen cross-sectional studies among HIV-positive women were included. Measurement of IPV 
varied, with most studies defining a 'case' as any history of physical and/or sexual IPV. Meta-analysis of five 
studies showed IPV to be significantly associated with lower ART use (OR=0.79, 95%CI 0.64-0.97). IPV was 
associated with poorer self-reported ART adherence in seven studies (OR=0.48, 95%CI 0.30-0.75) and 
lower odds of viral load suppression in seven studies (OR=0.64, 95%CI 0.46-0.90). Lack of longitudinal data 
and measurement considerations should temper interpretation of these results. 
 
Conclusions: IPV is associated with lower ART use, half the odds of self-reported ART adherence, and 
significantly worsened viral suppression among women. To ensure the health of HIV-positive women, it is 
essential for clinical programs to address conditions that impact engagement in care and treatment. IPV is 
one such condition, and its association with declines in ART use and adherence requires urgent attention.
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Introduction 
 
Advances in HIV care and treatment have led to remarkable health gains among those living with 
HIV. Yet, many HIV-positive patients remain out of care, fail to take up treatment, or are non-
adherent to antiretroviral therapy (ART). Such challenges with engagement in HIV are common 
among females [1, 2], and are responsible for a considerable proportion of morbidity and 
mortality among HIV-positive women [3, 4].  
 
There are a number of reasons for poor engagement in HIV care, among which intimate partner 
violence (IPV) has received increasing attention. IPV is defined as any behavior within an 
intimate relationship that causes physical, psychological or sexual harm [5], and global 
prevalence among is estimated to be 30% [6]. IPV has been associated with HIV infection in 
cross-sectional [7] and prospective studies [8, 9]. A meta-analysis of data from 28 studies showed 
that multiple forms of IPV are associated with incident HIV infection in women [10]. Research 
points to direct links between IPV and HIV infection, via forced sex, as well as indirect links, via 
heightened HIV risk among IPV perpetrators and a reduced ability for women in violent 
relationships to negotiate condom use [11-13].  
 
Despite this emerging literature around HIV acquisition, less is known about the influence of IPV 
for those already living with HIV. Evidence suggests that women living with HIV have a high 
likelihood of relationship violence. Clinical samples from resource-rich settings estimate that 68-
95% of HIV-positive women experience IPV in their lifetime [14-18]. In resource-constrained 
settings, HIV-positive women are twice as likely as HIV-negative counterparts to report lifetime 
violence from a partner [19]. HIV diagnosis, in itself, can trigger relationship conflict and 
violence [17, 20-22]. Importantly, HIV testing, regardless of the serostatus outcome, can lead to 
violence [23, 24], suggesting that even this first step in accessing care and treatment may pose an 
IPV risk. 
 
IPV leads to declines in HIV-related health, with studies finding an association between IPV and 
virologic failure [25, 26], lower CD-4 counts [25], higher incidence of opportunistic infection 
[26, 27], marked increase in episodic diseases (e.g. pneumonia, bronchitis, sinusitis) [27], and 
greater risk of mortality [28]. Negative effects on engagement in care and treatment may be a 
leading reason for IPV being associated with poor health outcomes for HIV-infected women.  
 
Several plausible mechanisms could drive the relationship between IPV and HIV-related 
engagement in care. Fear of new or continued IPV leads women to avoid disclosure of their status 
to male partners [29-31], which in turn has a significant impact on treatment adherence [32-34]. 
When women are fearful of violence from their partners, they may be more likely to default on 
medications or may have other health priorities, such as physical safety, that trump adherence 
[35]. Qualitative studies have explored how fear and experience of IPV influence women’s 
decisions to take up and stay retained in HIV services [35-37]. Given the well-established links 
between IPV and mental health [38-43], it is possible that poor mental health is the main 
explanation for how IPV impacts on ART adherence [44-47]. Alternately, feelings of denial and 
shame may preclude abused women’s abilities to seek care openly [48], or partner control may 
inhibit access to medical care [49]. 
 
Despite health risks associated with IPV among HIV-infected persons, IPV remains an 
understudied factor in the literature around HIV care and treatment [50]. Evidence on the 
association between IPV and adherence has yet to be reviewed systematically. This study 
examined the relationships between IPV and engagement in HIV care and treatment (ie. ART 
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uptake, ART adherence measured through self-report or by viral loads, and retention in HIV care) 
through a systematic review and meta-analysis. 
 
Methods 
 
A systematic review and meta-analyses were conducted on studies measuring an association 
between IPV and ART use, ART adherence (self-reported), ART adherence (viral suppression), 
and retention in HIV. The aim was to determine the extent to which IPV is related to engagement 
in HIV care and treatment among women.  
 
Selection criteria 
 
This review follows PRISMA reporting guidelines for systematic reviews (see Text S1) [51]. 
Studies were eligible for inclusion if they: 1) included adult women living with HIV; 2) presented 
primary, quantitative data in a peer-reviewed manuscript based on cross-sectional, case control, 
or longitudinal data; and 3) measured the predictor of interest (IPV) and at least one outcome of 
interest. No restrictions were placed on study setting or population.  
 
Search strategy 
 
Electronic searches were conducted using the following databases: PubMed, Web of Science, 
CINAHL, and PsychoInfo. Articles in English or French were included if they had been 
published in peer-reviewed journals before or up to January 2015. Search terms and a full search 
strategy can be found in Text S2.  
 
Study selection 
 
Using the “online search” function of EndNote [52], all titles and abstracts matching the search 
terms were imported. Two authors (AMH, EMS) independently reviewed all identified study 
titles and abstracts. Papers were retained if at least one search term for predictor or outcome 
concept was found. Abstracts that did not meet all inclusion criteria were excluded and reason for 
exclusion noted. Exclusion criteria included publication factors and population characteristics 
(Figure 1).  
 
The same authors (AMH, EMS) independently screened full papers of all included abstracts. Full 
papers with discrepancy about inclusion were reviewed by a third author (HS) to reach consensus. 
Exclusion reasons were noted. No additional study was identified by searching the reference lists 
of included articles. 
 
Data extraction 
 
Data were extracted on study design, setting, population, sample size, measures used to 
investigate IPV, and measures used to assess engagement in HIV care. As meta-analysis required 
data from among women only and in dichotomous outcomes, authors of several papers (n=7) 
were contacted directly via email and asked to abstract 2x2 tables in Excel: numbers of women 
reporting IPV vs. not and reporting engagement in care vs. not. Authors of all seven papers 
requiring additional information were willing and able to provide these data. 
 
Quality appraisal 
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A quality appraisal was conducted on all included studies using an adapted Critical Appraisal 
Skills Programme (CASP) quality appraisal tool (Text S3) [53]. The quality appraisal form 
includes 15 questions about study quality for which papers received a numeric score representing 
the extent to which they met the criteria: 0 (non responsive), 1 (partially responsive), or 2 (fully 
responsive).  
 
Data analysis 
 
Meta-analyses were conducted separately for dichotomous engagement in care outcomes. 
Dichotomous outcomes were deemed appropriate since key outcomes of interest were either 
inherently dichotomous (i.e. current ART use) or represented non-normally distributed 
continuous data (i.e. adherence, viral suppression). An assessment was made by the authorship 
team to ensure that “clinical heterogeneity” was acceptable to lend each outcome to meta-analysis 
[54].  
 
Quantitative outcomes were extracted into an Excel table. This included details on overall IPV 
prevalence in the study, cases and non-cases among women with IPV and without IPV, and 
correlation coefficients. Pooled unadjusted odds ratio (OR) estimates (with corresponding 95% 
confidence intervals) were calculated using random effects meta-analysis in STATA [55]. No 
adjustment was made for potential confounders, given that few studies reported covariate data. 
Heterogeneity among studies was estimated using the I2 statistic, with significant heterogeneity 
detected at the p<0.05 level. Sensitivity analysis for publication bias was undertaken through 
visual inspection of funnel plots [56] and Egger’s test statistic (with small-study effects being 
detectable at a conservative p<0.10 level) [57]. To aid comparison with other systematic reviews, 
the self-reported adherence outcome was transformed to a standardized mean difference [58]. 
 
Results 
 
Our search strategy identified 621 unique records, of which 554 were excluded during abstract 
screening (Figure 1). Full texts were obtained for 75 papers, of which 62 were excluded upon 
further screening. A total of thirteen studies measured the association between IPV and at least 
one of the primary outcomes: ART uptake, ART adherence (self-report), ART adherence (viral 
suppression), and retention in HIV care. 
 
Key features of included papers  
 
Table 1 presents the key characteristics and outcomes of the thirteen included studies [25, 59-70]. 
Most studies (n=11) were conducted in the United States and sample sizes across all studies were 
relatively small, with a median of 234 participants. All thirteen studies were cross-sectional. Most 
studies (n=12) were conducted among the general HIV-infected population, with Kalokhe et al. 
conducting their study among high-risk crack/cocaine users.  
 
Measures of Intimate Partner Violence 
 
Measures of IPV were based on self-reports across all thirteen studies. As shown in Table 1, 
several studies used brief, unvalidated screening tools to assess violence [59, 62-64]. Validated 
instruments included the Severity of Violence Against Women Scale [25, 66], the Conflict 
Tactics Scale [61], the Slapped, Threatened, and Throw instrument [60], and the Women’s 
Experience of Battering (WEB) scale [25, 67-69]. Ryerson Espino bolstered the WEB scale to 
include dimensions of forced sex and fears around physical safety [68]. Siemieniuk trained clinic 
researchers to conduct a standardized screening using a single introductory question about any 
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domestic abuse, after which women were considered to have IPV if they spoke in a semi-
structured way about violence as an adult within a current or past partner. [71].  
 
Eleven studies used lifetime experience of IPV as the exposure of interest, whereas two analyzed 
IPV in the past 12 months [59, 66]. Although several other papers included measures of recent 
violence (past 12 months [61, 68]; past 5 months [63]), the authors did not conduct analysis using 
the “recent violence” data.  
 
Ethical considerations 
 
Quality scores are reported in Table 1. All studies reported informed consent procedures and 
ethical review. However, Siemieniuk and Schafer were the only authors to detail specific steps 
taken by clinicians when women disclosed IPV [25, 65].  
 
Current ART use 
 
Five studies measured current ART use. Three studies used self-report of a single question (“are 
you currently on ART?”) to assess ART use at time of interview [60, 63, 67]. Two assessed 
current ART use via clinical data routinely collected in the HIV clinic [59, 65].  
 
No individual studies found a statistically significant relationship between IPV and current ART 
use among women. Siemieniuk found that participants who experienced IPV were more likely to 
report ART non-use, but this association did not reach statistical significance (p=0.069) [65]. 
Kalokhe found lower current ART use among 343 male and female cocaine users who had ever 
experienced IPV (p=0.001), but this relation [60]. Ramachandran found that men and women 
reporting a history of IPV were less likely to be using ART (66%) than non-abused counterparts 
(93%, p=0.04), but data were not available among women only [63]. Illangesekare found no 
significant association between experience of lifetime IPV and ART use in a sample of 196 HIV-
infected women (risk ratio [RR]=0.73, 95% confidence interval [CI] 0.39–1.42) [59]. Blank 
found no significant relationship between lifetime IPV and ART use (RR=1.01, 95%CI 0.88–
1.16) [67].  
 
ART adherence measured by Self-report  
 
Six studies included self-reported measures of ART adherence. Two used the AIDS Clinical 
Trials Group Questionnaire, which measures good adherence as greater than 90% in the past 3-
days and 30-days [61, 68]. Trimble used an adaptation of the Morisky Medication Adherence 
Scale [66], in which good adherence was defined as scores of 7 or higher. Participants in Malow’s 
study noted the percentage of time they took medicine as prescribed, with good adherence 
defined as 95% or greater [62]. Blank used the Case Adherence Index (CAI), dichotomized into 
poor adherence (=<10) or good adherence (>10) [67]. Rose asked the patient’s physician to rate 
on a scale of 0-10 how adherent they believed the patient to be, with good adherence assessed as 
>=9 [64]. 
 
Of the seven studies that assessed ART adherence using self-report, three found significant 
outcomes among women. Trimble found that mean adherence scores on the MMAS were 
significantly lower among women who reported IPV (M=5.49, SD=2.06) than among those 
without (M=6.57, SD=1.57, p<0.001) [66]. Using a dichotomous outcome, this translated to 
lower odds of good adherence among women reporting IPV (OR=0.28, 95%CI 0.17-0.47). Rose 
found poorer adherence among women with IPV as measured by the continuous outcome of 
physician-reported scale (r=-0.38, p<0.05) [64]. As a dichotomous outcome, women with IPV 
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had lower odds of good adherence (OR=0.15, 95%CI 0.03-0.70). Blank et al. found self-reported 
adherence was significantly worse among women who reported IPV (RR=0.74, 95%CI 0.72–
0.88) [67]. Lopez found that among women, “extreme IPV” (e.g. use of a weapon) was associated 
with decreased adherence as a continuous variable (r=-0.26, p=0.026) [61]. When using “any 
IPV” as the exposure of interest, Lopez did not find a significant difference (OR=0.45, 95%CI 
0.15-1.29). Ryerson Espino did not find a significant association, with a similar proportion of 
women reporting good adherence with (36.1%) and without IPV (40.0%) [68]. Malow did not 
find a significant direct association between IPV and non-adherence, but when using structural 
equation modeling, did find that partner conflict led to depression, which in turn was related to 
non-adherence [62].  
 
ART adherence measured by Viral Load 
 
Seven studies assessed adherence using patient medical records of viral load suppression. 
Dichotomized outcomes for viral load suppression used the clinically-relevant cut-off at the time 
of study: 500 copies/mL [65], 400 copies/mL [59] and 200 copies/mL [64, 67-70].  
 
Of the seven studies measuring viral load suppression, three found a significant association with 
IPV. Siemieniuk found that women experiencing IPV were more likely to have viral loads greater 
than 500 copies/mL than IPV-negative counterparts (p=0.027) [65]. Rose et al. also found a 
significant association, with the frequency of IPV related to increased HIV viral load (r=0.44, 
p<0.01) [64]. Espino found viral load suppression significantly lower among women reporting 
IPV (76.4%) than their counterparts (93.3%, X2=4.01 p<0.05) [68]. Illangesekare found no 
significant association between viral load of >400 copies/mL among those with IPV (59.6%) or 
without IPV (61.8%) [59]. Odds ratios reported in Blank, Schafer, and Sullivan were non-
significant ((OR=1.05, 95%CI 0.65-1.70); (OR=1.14, 95%CI 0.42-3.07); (OR=0.72, 95%CI 0.47-
1.10), respectively).  
 
Retention in HIV care 
 
Five studies measured retention in HIV care. Blackstock and Blank defined retention by any 
self-reported HIV medical care in the past 6 months [67, 70]. Kalokhe used self-report and asked 
participants “In the past 12 months have you gone to a doctor or clinic for HIV care?” [60]. 
Siemieniuk used patient medical records and defined poor retention in care as ever having had an 
interruption in clinical care greater than 365 days [65]. Schafer classified patients as having a 
high clinic no show rate (NSR >=33% missed visits) and low NSR (<33% missed visits) [25]. 
Because these retention measures have important conceptual differences, they were deemed too 
heterogeneous to lend this outcome to meta-analysis. 
 
Siemieniuk found that interruptions in clinical care were more common among women with a 
history of IPV (20.4% vs 11.9%, p=0.032) [65]. Kalokhe found that IPV positive participants 
were more likely to be out of care in the past 12 months (29.4 vs 18.8%, p=0.01) [60]. Neither 
Blackstock nor Blank found a significant relationship between IPV and any self-reported medical 
care in the past 6 months (OR=0.92 (0.68-1.24)) [67]. Schafer found no significant relationship 
between IPV and a high no show rate among women (OR=1.11 (0.27-4.60) [25]. 
 
Meta-analysis of engagement in care outcomes 
 
Meta-analysis suggests that IPV is associated significantly with lower odds of current ART use 
(Fig. 2; OR=0.79, 95%CI 0.64-0.97). However, since the extant literature shows heterogeneity 
(I2=68.9%, p=0.012), this finding should be interpreted cautiously.  
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The meta-analytical association suggests that IPV is associated with lower odds of self-reported 
adherence (Fig. 3; OR=0.48, 95%CI 0.30-0.75). Self-reported adherence also shows significant 
heterogeneity (I2=56.0%, p=0.044). To compare this outcome to other studies, the odds ratio was 
transformed into an effect size (standardized mean difference d=-0.404). 
 
There is a significant meta-analytic association between IPV and worsened viral load suppression 
(Fig. 4; OR=0.64, 95%CI 0.46-0.90), with acceptable level of agreement across studies 
(I2=41.2%, p=0.116).  
 
All meta-analyses were visually inspected for potential publication bias through funnel plots and 
Egger’s test for small-study effects. There was no evidence of publication bias for current ART 
use (Fig. S1; P=0.486), self-reported adherence (Fig. S2; P=0.859), or viral suppression (Fig. S3; 
P=0.176). 
 
Discussion 
 
Uptake and adherence to ART is a key pathway through which IPV may negatively influence 
HIV-related health of women globally. Meta-analysis suggests that IPV reduces the odds of ART 
adherence among women, a finding that is consistent when adherence is measured by self-report 
(OR=0.48, 95%CI 0.30-0.75) or viral load suppression (OR=0.64 95%CI 0.46-0.90). Adherence 
offers a potential explanation for why IPV has been linked to worsened clinical outcomes among 
HIV-positive women [25-28]. The meta-analytic effect size suggests that IPV exhibits a greater 
magnitude of association with ART adherence (d=-0.404) than other conditions such as 
depression, substance use, stigma, financial constraints, or pill burden [72].  
 
The causal pathway between IPV and engagement in HIV care and treatment is supported by 
related trauma literature. Mugavero et al. found that each additional episode of lifetime trauma 
was related to non-adherence even when controlling for depression, substance use, and race [73]. 
Cohen et al. found that a history of any type of physical or sexual abuse (including in childhood) 
increased the odds of women declining HAART when medically eligible [74]. These and other 
studies [73-80] were excluded from this systematic review because they analyzed IPV alongside 
other forms of violence (eg. childhood sexual abuse, non-partner violence). While such an 
approach may be useful conceptually, it will be crucial for future studies to prioritize clear and 
consistent measurement of IPV as a stand-alone construct.  
 
The current evidence base on IPV and HIV care has several important gaps. Nearly all studies 
were conducted in the United States, limiting translation to other settings globally. This 
geographic skew, though consistent with broader IPV literature [81, 82], warrants urgent attention 
since both HIV and IPV prevalence are high in regions such as sub-Saharan Africa [83, 84]. The 
few sub-Saharan African studies that do examine IPV among HIV-positive patients draw from 
couples who jointly take part in research and may come from relationships that are distinct from 
‘normal’ HIV-positive patients [85, 86].  
 
Measures for retention in HIV care were too disparate to be analyzed systematically. This 
shortcoming is suggestive of weaknesses in conceptualization of HIV care retention, which 
continues to lack a ‘gold standard’ measurement method [87]. We also found a lack of 
harmonization regarding the measurement of IPV, with comprehensive, validated measures 
employed in only three studies [60, 61, 66]. Since behaviourally-specific assessment of IPV helps 
elucidate the connections between violence and health outcomes [88], future research should 
employ comprehensive measures of IPV [89].  
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Another gap relates to the clinical nature of responding to violence disclosure in the research 
setting. Only two authors detailed specific steps taken by clinicians when women disclosed IPV 
[25, 65]. This represents a significant oversight given the well-established guidance around how 
to conduct IPV research in a clinically meaningful and ethically responsible way [90, 91]. 
 
A final research gap is the extant focus on the ‘general population’ of HIV-positive patients. It is 
possible that the association between violence and HIV-related outcomes may be distinct among 
other special populations (eg. adolescents, pregnant women, men who have sex with men, sex 
workers) and these sub-groups deserve attention in future research.  
 
Limitations 
 
There are several limitations of the current systematic review that should inform interpretation of 
findings. We focused the systematic review on HIV-positive women, but such a conceptualization 
should be followed by future work to understand IPV towards HIV-positive men. Literature 
included [60, 61, 63] and excluded [92-95] from this review illustrates that HIV-positive men 
experience challenges to engagement in care on par or in excess to those of women.  
 
Papers selected for final review have important limitations around comparability, given the 
variety of populations and sampling strategies used across the studies. There were no longitudinal 
studies included in this review, which suggests that meta-analytic findings can be viewed as a 
correlation but that IPV and engagement in care may not be causally related. Databases used may 
have inadvertently limited the search, although we attempted to compensate for this shortcoming 
by reviewing all citations included in the final set of full papers assessed (n=67). Interrater 
reliability was not formally assessed with regards to the selection of articles, but a third colleague 
was consulted to review any discrepancies in the inclusion/exclusion process.  
 
Conclusion 
 
In order to ensure HIV-related health among women, it is essential to address conditions that 
impact their ability to uptake and stay engaged in care and treatment. IPV is one such condition, 
and its association with declines in ART adherence requires urgent attention. Policy makers and 
programmers are beginning to recognize the central role that violence plays in the lives of women 
living with HIV [96, 97]. Yet, despite calls for violence screening and intervention within HIV 
care and treatment programs, few HIV clinics have IPV-specific protocols in place [98]. HIV care 
and treatment programs can draw upon existing guidelines for screening and responding to IPV in 
the health sector [91, 99], or can look to a growing number of specialist programs that address 
IPV alongside HIV [100-103]. To ensure that women benefit from medical advances, future 
studies should develop and test interventions to address IPV within HIV clinical care. 
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Table 1. Characteristics of included papers (n=13) 
 
 
 
Author Year 
Sample 
size 
(women) Population group  
Type of 
study Violence Measure Outcome of interest  Country 
CASP 
Quality 
Appraisal Type of IPV Measure 
Blackstock 2015 748 Women only 
Cross-
sectional 
10 item Women's 
Experience of Battering  
(WEB) Scale 
Retention (medical 
records) 
United 
States 20 
Ever, Physical and 
Psychological 
Blank* 2015 587 Women only 
Cross-
sectional 10 item (WEB) Scale 
Uptake (medical records), 
Adherence (self-report and 
viral suppression), 
Retention (medical 
records) 
United 
States 20 
Ever, Physical and 
Psychological 
Illangasekare 2012 196 Women only 
Cross-
sectional 
3 items from the Partner 
Violence Screen 
Uptake (medical records), 
Adherence (viral 
suppression) 
United 
States 16 
Past 12 months, Asked at 
1 timepoint, Physical, 
Psychological 
Kalokhe* 2012 175 
Women & Men 
(Crack/cocaine 
users, total 343) 
Cross-
sectional 
5 items from the 
Slapped, Threatened, 
and Throw (STaT) 
instrument 
Uptake (self-report), 
Retention  (medical 
records) 
United 
States 18 
Ever, Physical, Sexual, 
Psychological 
Lopez* 2010 94 
Women & Men 
(total 190) 
Cross-
sectional 
17 item Conflict Tactics 
Scale Adherence (self-report) 
United 
States 20 
Ever, Past 12 months, 
Physical, Sexual, 
Psychological 
Malow* 2013 166 
Women & Men 
(total 194) 
Cross-
sectional 
4 items from (unnamed) 
partner relationship scale Adherence (self-report) Haiti 20 
Ever, Physical, 
Psychological 
Table 1 Characteristics of included studies
Ramanchandran 2010 18 
Women & Men 
(total 56) 
Cross-
sectional 
3 items of Abuse 
Assessment Screen Uptake (self-report) 
United 
States 14 
Ever, Past 5 months, 
Physical, Sexual, 
Psychological 
Rose* 2010 40 Women only 
Cross-
sectional 
1 item from Traumatic 
Life Events 
Questionnaire 
Adherence (self-report and 
viral suppression) 
United 
States 15 Ever, Physical 
Ryerson Espino* 2015 102 Women only 
Cross-
sectional 
10 item (WEB) Scale 
plus 6 additional items 
on forced sex and fear 
Adherence (viral 
suppression) 
United 
States 22 
Ever, Past 12 months, 
Asked at multiple 
timepoints, Physical, 
Sexual, Psychological 
Schafer 2012 64 Women only 
Cross-
sectional 
46 item Severity of 
Violence Against 
Women Scale (SVAWS) 
instrument and 10 item 
WEB Scale 
Adherence (viral 
suppression), Retention 
(medical records) 
United 
States 20 
Ever, Physical, Sexual, 
Psychological 
Siemieniuk 2013 339 Women only 
Cross-
sectional 
Rich single-item 
screening question, 
assessed by interviewer 
as physical abuse,sexual 
abuse, emotional abuse, 
isolation, neglect, 
intimidation, and/or 
financial abuse 
Uptake (medical records), 
Adherence (viral 
suppression), Retention 
(medical records) 
United 
States 22 
Ever, Physical, Sexual, 
Psychological 
Sullivan* 2015 564 Women only 
Cross-
sectional 10 item WEB Scale 
Adherence (viral  
suppression) 
United 
States 22 
Ever, Physical, 
Psychological 
Trimble 2013 272 Women only 
Cross-
sectional 
46 item SVAWS 
instrument Adherence (self-report) 
United 
States 21 
Past 12 months, Physical, 
Sexual 
 
* Authors contacted for raw data on outcomes of interest. 
Original Search
n=757
Duplicates
n=136
Title / Abstract Screening
n=621
• Non-peer review (1)
• No analysis (29)
• Pop <18 years (43)
• Men only (20)
• Childhood Sexual 
Abuse only (40)
• Adherence to non-HIV 
medication (7)
• Adherence/uptake of 
post-exposure prophy-
laxis (49)
• Qualitative (31)
• Irrelevant (eg. animal 
research) (313)
Full Text Review
(up to January 2015)
n=75
• TOTAL Excluded (62)
• No primary data (36)
• Lacked predictor or 
outcome of interest 
(51)
• IPV measured as com-
posite with other types 
of violence (7)
• No women studied (3)
• Paper unavailable (0)
ART Adherence 
(Self-Report)
n=7
ART Uptake
n=5
• PubMed (133)
• Web of Sci (459)
• PsycInfo (86)
• CINAHL (79)
Retention in HIV Care
n=5
* 5 studies examined more than one outcome
ART Adherence 
(Viral Load Suppression)
n=7
Included
n=13*
Figure 1 Flowchart of primary study selection
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Figure 2 Meta-analysis of the association between IPV and current ART Use
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Figure 3 Meta-analysis of the association between IPV and self-reported ART adherence
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Figure 4 Meta-analysis of the association between IPV and viral load suppression
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